跳至主要内容
临床试验/NCT00600483
NCT00600483已完成3 期

A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Innocoll0 个研究点目标入组 1,502 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1,502
主要终点
Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90

研究概览

简要总结

The purpose of this study is to determine whether the gentamicin-collagen sponge is safe and effective in preventing sternal wound infections in patients undergoing cardiac surgery who are at a greater risk of developing sternal wound infections.

详细描述

Sternal wound infection (SWI) is a significant problem in cardiac surgical subjects,in particular in those with risk factors such as diabetes and obesity. There is a long unmet need for an intervention that can reduce the incidence and severity of SWIs in high-risk subjects.

Gentamicin is an antibiotic that is effective in treating certain kinds of infection. Collagen is a protein that is found in all mammals. The gentamicin-collagen sponge is a thin flat sponge made out of collagen that comes from cow tendons and containing gentamicin. When inserted into a surgical site, the collagen breaks down and the gentamicin is released at the site but very little is absorbed into the blood stream. The high levels of antibiotic at the surgical site may prevent an infection at the surgical site.

Outside of the United States more than 3,500 subjects have received treatment in clinical studies with the gentamicin-collagen sponge, primarily for orthopedic, intraabdominal, and cardiothoracic surgeries or wound infections following surgical procedures or traumatic events.

In this study, all subjects will be given treatment that is normally given to prevent surgical infections. For subjects randomly assigned to the gentamicin-collagen sponge treatment group, 2 sponges will be placed between the sternal halves during surgery. IMMEDIATELY before insertion of the sponge the surgeon should wet the sponge with saline as shown in the training/certification document. This wet sponge SHOULD BE INSERTED INTO THE STERNUM WITHIN APPROXIMATELY 15 SECONDS (AFTER THIS TIME IT MAY BECOME MORE DIFFICULT TO HANDLE). All subjects will be followed for 90 days after surgery to determine whether they develop a sternal wound infection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Scheduled to undergo nonemergent CABG and/or valve repair or replacement surgery through a full median sternotomy. This includes the following eligible procedures: isolated CABG surgery, isolated valve surgery, and combined CABG + valve surgery.
  • •Be at higher risk for SWI, defined as the presence of diabetes mellitus (treated with either oral agent or insulin) and/or obesity, defined as BMI >
  • •Have the capacity to understand and sign an informed consent form.
  • •Are male or female and > 18 years of age.
  • •If female, be postmenopausal (no menstrual period for a minimum of 1 year), be surgically sterilized and have a negative serum or urine pregnancy test on entry in the study, or agree to use adequate birth control during the study and for 3 months after the administration of study agent. Medically acceptable contraceptives include: (1) approved hormonal contraceptives (such as birth control pills, Depo-Provera, or Lupron Depot), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device (IUD).
  • •Agree to be available for evaluation from baseline until final evaluation at 90 days postsurgery.

排除标准

  • •Known history of hypersensitivity to gentamicin or bovine collagen.
  • •Undergoing emergency cardiac surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed).
  • •Undergoing a significant concomitant surgical procedure (eg, carotid endarterectomy, aortic root repair or replacement, DHCA, or pulmonary resection).
  • •Undergoing a minimally invasive or a thoracic surgical approach.
  • •Using a preoperative mechanical assist device or IABP if inserted for shock/low output syndrome (an IABP is allowed if it is inserted for unstable angina).
  • •Active and significant systemic infection, eg active endocarditis, or a history of significant recurrent systemic infection.
  • •Receiving antibiotic therapy within the 2 weeks before the date of surgery.
  • •Preoperative serum creatinine > 3 mg/dL or renal failure requiring dialysis.
  • •History of malignancy within the past year (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
  • •History of major organ transplantation, including bone marrow transplantation.
  • •Recent history of significant drug or alcohol abuse.
  • •Taking systemic immunosuppressive drugs, including steroids (at a dose > 10 mg oral prednisone daily) or a history of a current immunosuppressive condition (eg, symptomatic HIV infection), defined as a CD4 count <
  • •Scheduled to receive "stress doses" of glucocorticoids (ie, doses > 2 mg/kg/day of methylprednisolone or equivalent).
  • •Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability (defined in section 3.1).
  • •Postsurgical life expectancy ≤ 90 days, in the investigator's or sponsor's opinion.
  • •Refusal to accept medically indicated blood products.
  • •Current participation or participation within 30 days before the start of this study in another experimental drug or device study, or is currently participating in a study during which the administration of investigational drugs within 90 days is anticipated.
  • •Has a moderate or severe pectus deformity.

研究组 & 干预措施

gentamicin Group

Experimental

Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy

干预措施: gentamicin-collagen sponge dipped in saline (Drug)

结局指标

主要结局

Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 90

时间窗: 90 days post cardiac surgery

Efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections that occur within the period from surgery through postop day 90.

次要结局

  • Surgically Treated Surgical Wound Infection Postoperative Day 90(90 days post cardiac surgery)
  • Proportion of Patients With Deep Surgical Wound Infections Based on Centers for Disease Control Criteria Adjudicated by an Independent Blinded Committee.(90 days post cardiac surgery)
  • Proportion of Patients With Superficial Surgical Wound Infections Based on Centers for Disease Control Criteria Adjudicated by an Independent Blinded Committee.(90 days post cardiac surgery)
  • Number of Participants Positive for Each Pathogen Culture(90 days post cardiac surgery)
  • ASEPSIS Score(90 days post cardiac surgery)
  • Rehospitalization for Sternal Wound Infection(90 days post cardiac surgery)

研究者

发起方
Innocoll
申办方类型
Industry
责任方
Sponsor

相似试验